Data compiled by Redley Lamar · ChainSifter Intelligence
12Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
VolitionRx Limited (VNRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
27Total relationships
5Distinct source URLs
13High confidence
0.797Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from LIND graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from LIND graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from LIND g…
LIND-GLOBAL-ASSET-MANAGEMENT-XII-LLC
LIND-GLOBAL-ASSET-MANAGEMENT-XII-LLC
92%
VolitionRx Limited issued to Lind Global Asset Management XII LLC certain senior secured convertible promissory notes
VSTOCK-TRANSFER-LLC
VSTOCK-TRANSFER-LLC
92%
In connection with the Offering, the Company also entered into a warrant agent agreement with the Company’s transfer agent, VStock Transfer, LLC
HESKA
HESKA
85%
In exchange for granting Heska exclusive worldwide rights to sell our Nu.Q ® Vet Cancer Test at the point of care for companion animals, Volition received a $10.0 million upfront payment
FIRST-INSURANCE-FUNDING
FIRST-INSURANCE-FUNDING
80%
February 5, 2026, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $ 262,552
Reciprocal relationship from ABT graph: Reciprocal relationship from VNRX graph: ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or co…
ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products. · We expect to expand our product development, research…
EXAS
Exact Sciences Corp
72%
Reciprocal relationship from EXAS graph: Reciprocal relationship from VNRX graph: ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or c…
EXAS
Exact Sciences Corp
72%
ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products. · We expect to expand our product development, research…
Reciprocal relationship from MDXH graph: Reciprocal relationship from VNRX graph: ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or c…
ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products. · We expect to expand our product development, research…
VolitionRx Limited Customers
Ticker
Name
Confidence
Evidence
HESKA
HESKA
90%
On March 28, 2022, Volition entered into a master license and product supply agreement with Heska, now an Antech Company. | Qwen verified: VolitionRx is the customer as it receives license and produc…
HOLOGIC-DIAGENODE
HOLOGIC-DIAGENODE
90%
Under the agreement, Hologic will co-market Nu.Q ® Discover services with Hologic customers for an initial one-year term.
WERFEN
WERFEN
90%
Werfen also has an option to negotiate terms with Volition for it to launch the product commercially under an exclusive license.
Reciprocal relationship from ABT graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from ABT graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from ABT grap…
ies entering the market. The market for diagnostics is also significantly affected by new product introductions and other market activities of industry participants. Our competitors include large mul…
EXAS
Exact Sciences Corp
72%
ies entering the market. The market for diagnostics is also significantly affected by new product introductions and other market activities of industry participants. Our competitors include large mul…
EXAS
Exact Sciences Corp
72%
Reciprocal relationship from EXAS graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from EXAS graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from EXAS g…
Reciprocal relationship from MDXH graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from MDXH graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from MDXH g…
ies entering the market. The market for diagnostics is also significantly affected by new product introductions and other market activities of industry participants. Our competitors include large mul…
VETERINARY-PATHOLOGY-GROUP
VETERINARY-PATHOLOGY-GROUP
62%
eement with Heska, now an Antech Company. In exchange for granting Heska exclusive worldwide rights to sell our Nu.Q ® Vet Cancer Test at the point of care for companion animals, Volition received a …
VOLITION-GERMANY-GMBH
VOLITION-GERMANY-GMBH
62%
on 357,263 The following table combines the 2025 and 2026 Lind Note repayments and associated debt discount amounts. For the Three Months Ending March 31, 2026 Amount $ 2026 - Remaining 5,450,000 202…
VolitionRx Limited Debt Obligations
Instrument
Description
Confidence
Evidence
VNRX-DEBT
Debt stack $6.6M
90%
Market cache reports total debt of $6.6M.
VNRX-DEBT-13406
Warrants outstanding: 0.45
90%
xbrl warrant detail from xbrl 2026-03-31.
VNRX-DEBT-13407
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2026-03-31.
VolitionRx Limited Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for VolitionRx Limited.
VolitionRx Limited Ownership
Holder
Name
Confidence
Evidence
VNRX-OWNER-LAGODA-INVESTMENT-MANAGEMENT-L-P
Lagoda Investment Management, L.P.
90%
13F overlay lists Lagoda Investment Management, L.P. as top holder; 32 tracked holders.
